Skip to main content
Caplight Logo









RetiSpec

RetiSpec

Private
TorontoHealthcare & Life Scienceshttps://www.retispec.com/

Last Round

Series A

Jul 26, 2024

Total Funding Raised

$17M

Company Overview

RetiSpec is a health tech company that provides a platform for the early detection of neurodegenerative diseases through a non-invasive eye exam.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

hyperspectral imagingretinal imagingAlzheimer's diagnosticsmedical AIneurodegenerative disease screeningdigital biomarkernon-invasive diagnosticsAI diagnosticseye exam AIclinical trial softwarepoint-of-care diagnosticsexplainable AIXAImedtechhealthtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RetiSpec Comparables

Compare RetiSpec with similar companies based on industry and business-model similarity.

RetiSpec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Optina Diagnostics
91%
NeuroVision Imaging
87%
Cognoptix
78%

RetiSpec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 26, 2024
GrantJul 7, 2023
GrantApr 13, 2023
GrantMay 25, 2022
SeedFeb 1, 2020
Grant
Oct 8, 2019

Key People

Founding team and executive leadership

Eliav Shaked

CEO

Executive Team

RetiSpec Investors

Notable investors and investment history

RetiSpec investors
InvestorRounds
Ontario Brain InstituteGrant, Seed, Series A
Verge HealthTech FundSeed, Series A
Discovery Capital FundingSeed, Series A
Davos Alzheimer's CollaborativeGrant
iGan PartnersSeries A
Centre for Aging and Brain Health InnovationSeed, Series A, Grant
Alzheimer's Drug Discovery FoundationGrant, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2024

    $10M round led by iGan Partners.

  • Apr 13, 2023

    Received grant funding from Centre for Aging and Brain Health Innovation.

RetiSpec Filings

Explore SEC and related filing metadata, where available.

RetiSpec filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RetiSpec's valuation, stock price, and market status.

Is RetiSpec a public or private company?

RetiSpec is a private company.

What is the current stock price of RetiSpec?

RetiSpec is a private company with no public stock price. No recent secondary market data is available.

How much is RetiSpec worth (valuation)?

Valuation information for RetiSpec is not publicly available.

Can I buy RetiSpec stock?

RetiSpec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was RetiSpec's last funding round?

RetiSpec's most recent funding round was Series A on July 26, 2024.

Who are the main investors in RetiSpec?

Key investors in RetiSpec include iGan Partners.

Will RetiSpec IPO soon?

No public IPO plans have been announced for RetiSpec.

How can I track RetiSpec secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RetiSpec's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToronto
Employee Range27
Year Founded2016
Last FundingJul 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?